Hellmann MD, et al. Efficacy/Safety of Entinostat (ENT) and Pembrolizumab (PEMBRO) in NSCLC Patients Previously Treated with Anti-PD-(L)1 Therapy. IASLC 2018, abstract OA05.01.
Sneller starten met behandeling niet geassocieerd met betere overleving NSCLC
jun 2023 | Immuuntherapie, Longoncologie, Radiotherapie